Secukinumab Shows No Significant Benefit in Giant Cell Arteritis Study

Results from the Phase 3 GCAptAIN study, published in NEJM Evidence, indicate that the interleukin-17A inhibitor secukinumab did not offer a significant advantage over a placebo for treating giant cell arteritis. This finding, when the drug was combined with tapering doses of glucocorticoids, suggests secukinumab may not be an effective treatment option for this common form of vasculitis in older adults.